Advances in the epidemiology, diagnosis and treatment of cryptosporidiosis

References

• Thompson RC, Olson ME, Zhu G, Enomoto S, Abrahamsen MS, Hijjawi NS. Cryptosporidium and cryptosporidiosis. Adv. Parasitol.59, 77–158 (2005).
   PubMed Web of Science ®Google Scholar
• Cacciò SM. Molecular epidemiology of human cryptosporidiosis. Parassitologia47(2), 185–192 (2005).
   PubMedGoogle Scholar
• Xiao L, Fayer R, Ryan U, Upton SJ. Cryptosporidium taxonomy: recent advances and implications for public health. Crit. Rev. Microbiol.17, 72–97 (2004).
   Google Scholar
• Fayer R, Morgan U, Upton SJ. Epidemiology of Cryptosporidium: transmission, detection and identification. Int. J. Parasitol.30(12–13), 1305–1322 (2000).
   PubMed Web of Science ®Google Scholar
• Dillingham RA, Lima AA, Guerrant RL. Cryptosporidiosis: epidemiology and impact. Microbes Infect.4(10), 1059–1066 (2002).
   PubMed Web of Science ®Google Scholar
• Gomez Morales MA, Ausiello CM, Urbani F, Pozio E. Crude extract and recombinant protein of Cryptosporidium parvum oocysts induce proliferation of human peripheral blood mononuclear cells in vitro. J. Infect. Dis.172, 211–216 (1995).
   PubMed Web of Science ®Google Scholar
• Current WL, Reese NC, Ernst JV, Bailey WS, Heyman MB, Weinstein WM. Human cryptosporidiosis in immunocompetent and immunodeficient persons. Studies of an outbreak and experimental transmission. N. Engl. J. Med.308, 1252–1257 (1983).
   PubMed Web of Science ®Google Scholar
• Hunter PR, Chalmers RM, Syed Q, Hughes LS, Woodhouse S, Swift L. Foot and mouth disease and cryptosporidiosis: possible interaction between two emerging infectious diseases. Emerg. Infect. Dis.9, 109–112 (2003).
   PubMed Web of Science ®Google Scholar
• Smerdon WJ, Nichols T, Chalmers RM, Heine H, Reacher MH. Foot and mouth disease in livestock and reduced cryptosporidiosis in humans, England and Wales. Emerg. Infect. Dis.9(1), 22–28 (2003).
   PubMed Web of Science ®Google Scholar
• Sopwith W, Osborn K, Chalmers R, Regan M. The changing epidemiology of cryptosporidiosis in North West England. Epidemiol. Infect.133, 785–793 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou L, Singh A, Jiang J, Xiao L. Molecular surveillance of Cryptosporidium spp. in raw wastewater in Milwaukee: implications for understanding outbreak occurrence and transmission dynamics. J. Clin. Microbiol.41, 5254–5257 (2003).
   PubMed Web of Science ®Google Scholar
• Cacciò SM, Thompson RC, McLauchlin J, Smith HV. Unravelling Cryptosporidium and Giardia epidemiology. Trends Parasitol.21(9), 430–437 (2005).
   PubMed Web of Science ®Google Scholar
• Goh S, Reacher M, Casemore DP et al. Sporadic cryptosporidiosis, North Cumbria, England, 1996–2000. Emerg. Infect. Dis.10, 1007–1015 (2004).
   PubMed Web of Science ®Google Scholar
• Stantic-Pavlinic M, Xiao L, Glaberman S et al. Cryptosporidiosis associated with animal contacts. Wien Klin. Wochenschr.15, 125–127 (2003).
   Google Scholar
• Hunter P, Thomspon RC. The zoonotic transmission of Giardia and Cryptosporidium. Int. J. Parasitol.35(11–12), 1181–1190 (2005).
   PubMed Web of Science ®Google Scholar
• Fayer R. Cryptosporidium: a water-borne zoonotic parasite. Vet. Parasitol.126, 37–56 (2004).
   PubMed Web of Science ®Google Scholar
• MacKenzie WR, Hoxie NJ, Proctor ME et al. A massive outbreak in Milwaukee of Cryptosporidium infection transmitted through the public water supply. N. Engl. J. Med.331, 161–167 (1994).
   PubMed Web of Science ®Google Scholar
• Corso PS, Kramer MH, Blair KA, Addiss DG, Davis JP, Haddix AC. Cost of illness in the 1993 waterborne Cryptosporidium outbreak, Milwaukee, Wisconsin. Emerg. Infect. Dis.9, 426–431 (2003).
   PubMed Web of Science ®Google Scholar
• Slifko TR, Smith HV, Rose JB. Emerging parasite zoonoses associated with water and food. Int. J. Parasitol.30, 1379–1393 (2000).
   PubMed Web of Science ®Google Scholar
• Millar BC, Finn M, Xiao L, Lowery CJ, Dooley JSG, Moore JE. Cryptosporidium in foodstuffs: an emerging aetiological route of human foodborne illness. Trends Food Sci. Technol.3, 168–187 (2002).
   Google Scholar
• Fayer R, Dubey JP, Lindsay DS. Zoonotic protozoa: from land to sea. Trends Parasitol.20, 531–536 (2004).
   PubMed Web of Science ®Google Scholar
• Miller WA, Miller MA, Gardner IA et al. New genotypes and factors associated with Cryptosporidium detection in mussels (Mytilus spp.) along the California coast. Int. J. Parasitol.35(10), 1103–1113 (2005).
   PubMed Web of Science ®Google Scholar
• Hunter PR, Nichols G. Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients. Clin. Microbiol. Rev.15, 145–154 (2002).
   PubMed Web of Science ®Google Scholar
• Pozio E, Rezza G, Boschini A et al. Clinical cryptosporidiosis and human immunodeficiency virus (HIV)-induced immunosuppression: findings from a longitudinal study of HIV-positive and HIV-negative former injection drug users. J. Infect. Dis.176, 969–975 (1997).
   PubMed Web of Science ®Google Scholar
• Hayward AR, Levy J, Facchetti F et al. Cholangiopathy and tumours of the pancreas, liver and biliary tree in boys with X-linked immunodeficiency with hyper-IgM syndrome. J. Immunol.158, 977–983 (1997).
   PubMed Web of Science ®Google Scholar
• McLauchlin J, Amar CFL, Pedraza-Diaz S, Mieli-Verganti G, Hadzic N, Davies EG. Polymerase chain reaction-based diagnosis of infection with Cryptosporidium in children with primary immunodeficiencies. Pediatr. Infect. Dis. J.22, 329–334 (2003).
   PubMed Web of Science ®Google Scholar
• Gomez Morales MA, Ausiello CM, Guarino A et al. Severe, protracted intestinal cryptosporidiosis associated with interferon-deficiency: pediatric case report. Clin. Infect. Dis.22, 848–850 (1996).
   PubMed Web of Science ®Google Scholar
• Pozio E, Rivasi F, Cacciò SM. Infection with Cryptosporidium hominis and reinfection with Cryptosporidium parvum in a transplanted ileum. APMIS112, 309–313 (2004).
   PubMed Web of Science ®Google Scholar
• Thomas AG, Phillips AD, Walker-Smith JA. Cryptosporidiosis in England and Wales: prevalence and clinical and epidemiological features. Public Health Laboratory Service Study Group. Br. Med. J.300, 774–777 (1990).
   PubMedGoogle Scholar
• Sulaiman IM, Hira PR, Zhou L et al. Unique endemicity of cryptosporidiosis in children in Kuwait. J. Clin. Microbiol.43(6), 2805–2809 (2005).
   PubMed Web of Science ®Google Scholar
• Berkman DS, Lescano AG, Gilman RH, Lopez SL, Black MM. Effects of stunting, diarrheal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study. Lancet359, 564–571 (2002).
   PubMed Web of Science ®Google Scholar
• Tumwine JK, Kekitiinwa A, Nabukeera N et al. Cryptosporidium parvum in children with diarrhea in Mulago Hospital, Kampala, Uganda. Am. J. Trop. Med. Hyg.68(6), 710–715 (2003).
   PubMed Web of Science ®Google Scholar
• Roy SL, DeLong SM, Stenzel SA et al. Risk factors for sporadic cryptosporidiosis among immunocompetent persons in the United States from 1999–2001. J. Clin. Microbiol.42, 2944–2951 (2004).
   PubMed Web of Science ®Google Scholar
• Robertson B, Sinclair MI, Forbes AB et al. Case-control studies of sporadic cryptosporidiosis in Melbourne and Adelaide, Australia. Epidemiol. Infect.128, 419–431 (2002).
   PubMed Web of Science ®Google Scholar
• Hunter PR, Hughes S, Woodhouse S et al. Sporadic cryptosporidiosis case-control study with genotyping. Emerg. Infect. Dis.10, 1241–1249 (2004).
   PubMed Web of Science ®Google Scholar
• Hunter PR, Hughes S, Woodhouse S et al. Health sequelae of human cryptosporidiosis in immunocompetent patients. Clin. Infect. Dis.39, 504–510 (2004).
   PubMed Web of Science ®Google Scholar
• Arrowood MJ. Diagnosis. In: Cryptosporidium and Cryptosporidiosis. Fayer R (Ed.), CRC Press, New York, London and Tokyo, 43–64 (1997).
   Google Scholar
• Rondanelli EG, Scaglia M. Atlas of Human Protozoa. Masson, Milan, Paris and Bonn (1993).
   Google Scholar
• Gomez Morales MA, Pozio E, Croppo GP. Serodiagnosis of human cryptosporidiosis in Italian HIV+ patients using a soluble antigen by ELISA. J. Infect.25, 229–236 (1992).
   PubMed Web of Science ®Google Scholar
• Priest JW, Li A, Khan M et al. Enzyme immunoassay detection of antigen-specific immunoglobulin G antibodies in longitudinal serum samples from human cryptosporidiosis patients. Clin. Diagn. Lab. Immunol.8, 415–423 (2001).
   PubMedGoogle Scholar
• Cacciò SM. Molecular techniques to detect and identify protozoan parasites in the environment. Acta Microbiol. Pol.52, 23–34 (2003).
   PubMedGoogle Scholar
• Armson A, Thompson RC, Reynoldson JA. A review of chemotherapeutic approaches to the treatment of cryptosporidiosis. Expert Rev. Anti Infect. Ther.1(2), 297–305 (2003).
   PubMedGoogle Scholar
• White CA Jr. Nitazoxanide: a new broad spectrum antiparasitic agent. Expert Rev. Anti Infect. Ther.2(1), 43–49 (2004).
   PubMedGoogle Scholar
• Gentile G, Venditti M, Micozzi A et al. Cryptosporidiosis in patients with hematologic malignancies. Rev. Infect. Dis.13, 842–846 (1991).
   PubMedGoogle Scholar
• Saez-Llorens X, Odio CM, Umana MA, Morales MV. Spiramycin vs. placebo for treatment of acute diarrhea caused by Cryptosporidium. Pediatr. Infect. Dis. J.8, 136–140 (1989).
   PubMed Web of Science ®Google Scholar
• Moskovitz BL, Stanton TL, Kusmierek JJ. Spiramycin therapy for cryptosporidial diarrhoea in immunocompromised patients. J. Antimicrob. Chemother.22(Suppl. B), 189–191 (1988).
   PubMed Web of Science ®Google Scholar
• Portnoy D, Whiteside ME, Buckley E III, MacLeod CL. Treatment of intestinal cryptosporidiosis with spiramycin. Ann. Intern. Med.101, 202–204 (1984).
   PubMed Web of Science ®Google Scholar
• Kadappu KK, Nagaraja MV, Rao PV, Shastry BA. Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease. J. Postgrad. Med.48, 179–181 (2002).
   PubMedGoogle Scholar
• Chokephaibulkit K, Wanachiwanawin D, Tosasuk K, Pavitpok J, Vanprapar N, Chearskul S. Intestinal parasitic infections among human immunodeficiency virus-infected and -uninfected children hospitalized with diarrhea in Bangkok, Thailand. Southeast Asian J. Trop. Med. Public Health32, 770–775 (2001).
   PubMedGoogle Scholar
• Dionisio D, Orsi A, Sterrantino G et al. Chronic cryptosporidiosis in patients with AIDS: stable remission and possible eradication after long-term, low dose azithromycin. J. Clin. Pathol.51, 138–142 (1998).
   PubMed Web of Science ®Google Scholar
• Hicks P, Zwiener RJ, Squires J, Savell V. Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. J. Pediatr.129, 297–300 (1996).
   PubMed Web of Science ®Google Scholar
• Jordan WC. Clarithromycin prophylaxis against Cryptosporidium enteritis in patients with AIDS. J. Natl Med. Assoc.88, 425–427 (1996).
   PubMed Web of Science ®Google Scholar
• Holmberg SD, Moorman AC, Von Bargen JC et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. JAMA279, 384–386 (1998).
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Zackin R, Feinberg J, Benson C, Griffiths JK; AIDS Clinical Trials Group New Works Concept Sheet Team 064. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. AIDS14, 2889–2893 (2000).
   PubMed Web of Science ®Google Scholar
• Hewitt RG, Yiannoutsos CT, Higgs ES et al. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin. Infect. Dis.31, 1084–1092 (2000).
   PubMed Web of Science ®Google Scholar
• White AC Jr, Chappell CL, Hayat CS, Kimball KT, Flanigan TP, Goodgame RW. Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. J. Infect. Dis.170, 419–424 (1994).
   PubMed Web of Science ®Google Scholar
• Bissuel F, Cotte L, Rabodonirina M, Rougier P, Piens MA, Trepo C. Paromomycin: an effective treatment for cryptosporidial diarrhea in patients with AIDS. Clin. Infect. Dis.18, 447–449 (1994).
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Ritchie DJ, Powderly WG. Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clin. Infect. Dis.16, 298–300 (1993).
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Hidalgo H, Feregrino M et al. A double-blind placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans. R. Soc. Trop. Med. Hyg.92, 663–666 (1998).
   PubMed Web of Science ®Google Scholar
• Doumbo O, Rossignol JF, Pichard E et al. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg.56, 637–639 (1997).
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J. Infect. Dis.184, 103–106 (2001).
   PubMed Web of Science ®Google Scholar
• Amadi B, Mwiya M, Musuku J et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet360, 1375–1380 (2002).
   PubMed Web of Science ®Google Scholar
• Nachbaur D, Kropshofer G, Feichtinger H, Allerberger F, Niederwieser D. Cryptosporidiosis after CD34-selected autologous peripheral blood stem cell transplantation (PBSCT). Treatment with paromomycin, azithromycin and recombinant human interleukin-2. Bone Marrow Transplant.19, 1261–1263 (1997).
   PubMed Web of Science ®Google Scholar
• Smith NH, Cron S, Valdez LM, Chappell CL, White AC Jr. Combination drug therapy for cryptosporidiosis in AIDS. J. Infect. Dis.178, 900–903 (1998).
   PubMed Web of Science ®Google Scholar
• Riggs MW. Recent advances in cryptosporidiosis: the immune response. Microbes Infect.4(10), 1067–1080 (2002).
   PubMed Web of Science ®Google Scholar
• Okhuysen PC, Chappell CL, Crabb J, Valdez LM, Douglass ET, DuPont HL. Prophylactic effect of bovine anti-Cryptosporidium hyperimmune colostrum immunoglobulin in healthy volunteers challenged with Cryptosporidium parvum.Clin. Infect. Dis.26(6), 1324–1329 (1998).
   PubMed Web of Science ®Google Scholar
• Pozio E, Gomez Morales MA. The impact of HIV-protease inhibitors on opportunistic parasites. Trends Parasitol.21(2), 58–63 (2005).
   PubMed Web of Science ®Google Scholar
• Babiker A, Darbyshire J, Pezzotti P et al. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int. J. Epidemiol.31(5), 951–958 (2002).
   PubMed Web of Science ®Google Scholar
• Miao YM, Awad-El-Kariem FM, Franzen C et al. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. J. Acquir. Immune Defic. Syndr.25, 124–129 (2000).
   PubMed Web of Science ®Google Scholar
• Call SA, Heudebert G, Saag M, Wilcox CM. The changing etiology of chronic diarrhea in HIV-infected patients with CD4 cell counts less than 200 cells/mm3. Am. J. Gastroenterol.95, 3142–3146 (2000).
   PubMed Web of Science ®Google Scholar
• Monkemuller KE, Call SA, Lazenby AJ, Wilcox CM. Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy. Am. J. Gastroenterol.95, 457–462 (2000).
   PubMed Web of Science ®Google Scholar
• Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J. Infect.42, 134–139 (2001).
   PubMed Web of Science ®Google Scholar
• Conti S, Masocco M, Pezzotti P et al. Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses. J. Acquir. Immune Defic. Syndr.25, 451–458 (2000).
   PubMed Web of Science ®Google Scholar
• Schmidt W, Wahnschaffe U, Schafer M et al. Rapid increase of mucosal CD4 T cells followed by clearance of intestinal cryptosporidiosis in an AIDS patient receiving highly active antiretroviral therapy. Gastroenterology120, 984–987 (2001).
   PubMed Web of Science ®Google Scholar
• Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet351, 256–261 (1998).
   PubMed Web of Science ®Google Scholar
• Grube H, Ramratnam B, Ley C, Flanigan TP. Resolution of AIDS associated cryptosporidiosis after treatment with indinavir. Am. J. Gastroenterol.92, 726 (1997).
   PubMed Web of Science ®Google Scholar
• Maggi P, Larocca AM, Quarto M, Serio G, Brandonisio O, Angarano G, Pastore G. Effect of antiretroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1. Eur. J. Clin. Microbiol. Infect. Dis.19, 213–217 (2000).
   PubMed Web of Science ®Google Scholar
• Mele R, Gomez Morales MA, Tosini F, Pozio E. Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models. Int. J. Parasitol.33, 757–764 (2003).
   PubMed Web of Science ®Google Scholar
• Hommer V, Eichholz J, Petry F. Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum. J. Antimicrob. Chemother.52, 359–364 (2003).
   PubMed Web of Science ®Google Scholar
• Abrahamsen MS, Templeton TJ, Enomoto S et al. Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science304, 441–445 (2004).
   PubMed Web of Science ®Google Scholar
• Xu P, Widmer G, Wang Y et al. The genome of Cryptosporidium hominis. Nature431, 1107–1112 (2004).
   PubMed Web of Science ®Google Scholar
• Wiesner J, Seeber F. The plastid-derived organelle of protozoan human parasites as a target of established and emerging drugs. Expert Opin. Ther. Targets9, 23–44 (2005).
   PubMed Web of Science ®Google Scholar
• Camps M, Arrizabalaga G, Boothroyd J. An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii. Mol. Microbiol.43, 1309–1318 (2002)
   PubMed Web of Science ®Google Scholar
• Baggish AL, Hill DR. Antiparasitic agent atovaquone. Antimicrob. Agents Chemother.46, 1163–1173 (2002).
   PubMed Web of Science ®Google Scholar
• Striepen B, Pruijssers AJ, Huang J et al. Gene transfer in the evolution of parasite nucleotide biosynthesis. Proc. Natl Acad. Sci. USA101, 3154–3159 (2001).
   Google Scholar
• Umejiego NN, Li C, Riera T, Hedstrom L, Striepen B. Cryptosporidium parvum IMP dehydrogenase: identification of functional, structural, and dynamic properties that can be exploited for drug design. J. Biol. Chem.279, 40320–40327 (2004).
   PubMed Web of Science ®Google Scholar